The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2025 | The CLL2-BZAG trial: MRD-guided zanubrutinib, venetoclax, and obinutuzumab in R/R CLL
In this video, Moritz Fürstenau, MD, University Hospital of Cologne, Cologne, Germany, comments on the findings from the CLL2-BZAG trial (NCT04515238). This study investigated the use of measurable residual disease (MRD)-guided treatment with a triplet combination of zanubrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2025 in Krakow, Poland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In the BZAG trial we tested a combination of venetoclax, obinutuzumab and zanubrutinib in an MRD-guided fashion. So patients got at least 14 cycles, 14 months of combination treatment, but when they did not achieve undetectable MRD at a certain time point, they could continue treatment for up to almost three years. And what we found is that the rates of undetectable MRD were quite high, and we hardly saw any progression so far...
In the BZAG trial we tested a combination of venetoclax, obinutuzumab and zanubrutinib in an MRD-guided fashion. So patients got at least 14 cycles, 14 months of combination treatment, but when they did not achieve undetectable MRD at a certain time point, they could continue treatment for up to almost three years. And what we found is that the rates of undetectable MRD were quite high, and we hardly saw any progression so far. So I think we had two or three progressions only, with a relatively short follow-up. But it shows that in a really heavily pre-treated patient population with also a lot of high-risk features genetically, we were able to induce deep remissions with this triplet combination.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
